✦ LIBER ✦

p16 inactivation in small-sized lung adenocarcinoma: Its association with poor prognosis

✍ Scribed by Beniyo Kawabuchi; Sachiko Moriyama; Mitsugu Hironaka; Takeshi Fujii; Morio Koike; Hirokazu Moriyama; Yoshihiro Nishimura; Shoichi Mizuno; Masashi Fukayama

Publisher: John Wiley and Sons
Year: 1999
Tongue: French
Weight: 105 KB
Volume: 84
Category: Article
ISSN: 0020-7136
DOI: 10.1002/(sici)1097-0215(19990219)84:1<49::aid-ijc10>3.0.co;2-y

No coin nor oath required. For personal study only.

✦ Synopsis

p16, an inhibitor of cell cycle machinery, is frequently inactivated in non-small cell carcinoma of the lung (NSCCL). To clarify the significance of p16 inactivation in the progression of lung adenocarcinoma, we immunohistochemically evaluated p16 protein status and Rb, p53 and cyclin D1 expression in 51 surgically resected adenocarcinomas that were less than 3 cm in diameter (median follow-up period: 52.5 months). Twenty-one of 51 adenocarcinomas showed negative immunostaining for p16. Twenty adenocarcinomas were also negative for Rb, while 31 and 13 were positive for p53 and cyclin D1, respectively. Loss of p16 expression was significantly correlated with scar grade, lymphatic permeation, lymph node metastasis and clinical stage. Rb protein expression was also inversely correlated with scar grade, pleural involvement and vascular invasion. When the cases were stratified according to the expression of both proteins, the Rb-/p16- subset (7/51) consisted of poorly differentiated adenocarcinoma with a higher grade of invasion. While Rb, p53 and cyclin D1 protein status showed no significant correlations with prognosis, p16 inactivation was significantly correlated with poor prognosis, and the prognosis of Rb-/p16- was the worst among the 4 subsets. Inactivation of p16 may play a role in accelerating scar formation and lymph node metastasis, and may contribute through these mechanisms to poor prognosis in patients with small-sized lung adenocarcinoma.

📜 SIMILAR VOLUMES

c-erbB-2 Expression in small-cell lung c

c-erbB-2 Expression in small-cell lung cancer is associated with poor prognosis

✍ Patrick Micke; Jan Georg Hengstler; Roser Ros; Fernando Bittinger; Tsegay Metz; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 277 KB

## Small -cell lung cancer (SCLC) carries a bad prognosis despite good initial response to chemotherapy. It is therefore important to identify molecular markers that influence survival as potential new therapeutic targets. In our study, expression of the tyrosine kinase c-erbB-2 (HER2/neu) recepto

Frequent genomic loss at chr16p13.2 is a

Frequent genomic loss at chr16p13.2 is associated with poor prognosis in colorectal cancer

✍ Claus Lindbjerg Andersen; Philippe Lamy; Kasper Thorsen; Eigil Kjeldsen; Friedri 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 862 KB

## Abstract Genomic alterations play important roles in colorectal cancer (CRC) carcinogenesis. Here, we aimed to identify and characterize recurrent copy‐number alterations (CNAs) associated with clinical outcome of CRC by the use of single nucleotide polymorphism arrays, genomic quantitative PCR

Alterations of the Rb gene and its assoc

Alterations of the Rb gene and its association with ki-ras activation and p53 inactivation in endometrial adenocarcinoma

✍ Takayuki Enomoto; Taisei Nomura; Masami Fujita; Masaki Inoue; Aiko Nakazawa-Miya 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 630 KB

## Abstract Alterations of the retinoblastoma (__Rb__) gene were evaluated in nine primary endometrial adenocarcinomas that we had previously analyzed for the presence of Ki‐__ras__ activations and __p53__ alterations and in three endometrial carcinoma cell lines. Loss of mRNA expression in the __R

Inactivation of p16/CDKN2 and p15/MTS2 i

Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer

✍ Kazuya Kudoh; Yoshihito Ichikawa; Sadao Yoshida; Misako Hirai; Yoshihiro Kikuchi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 130 KB

## Abstract To define the involvement of __p16/CDKN2__ and __p15/MTS2__ tumor‐suppressor genes for response to chemotherapy in primary epithelial ovarian cancer, we analyzed alterations of the gene in 45 patients who were treated with primary cytoreductive surgery followed by 6 courses of cis‐diamm

Phase II trial of vindesine and VP16-213

Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer

✍ Simon G. Allan; Anna Gregor; Michael A. Cornbleet; Robert C. F. Leonard; John F. 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 320 KB

Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR

Identification of the small interstitial

Identification of the small interstitial deletion at chromosome band 1p34–p35 and its association with poor outcome in oligodendroglial tumors

✍ Toshihiko Iuchi; Hiroki Namba; Yasuo Iwadate; Tomotane Shishikura; Hajime Kageya 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 432 KB

## Abstract To narrow down the putative tumor‐suppressor gene locus and to assess the predictability of clinical courses by genomic alterations, we analyzed 46 oligodendroglial tumors for loss of heterozygosity (LOH) in the distal region of the short arm of chromosome 1. LOH at 1p was found in 43 t